PD-L1
44 programs · 43 companies
Programs
44
Companies
43
Active Trials
34
Targeting PD-L1
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | TTR Amyloidosis | |
| Olpatinib | GSK | Preclinical | MSAS | |
| BAY-3684 | Bayer | Approved | NMOSD | |
| Polatuximab | Nuvalent | Approved | Ovarian CaPNH | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | Prostate Ca | |
| Voxaderotide | Viking Therapeutics | Approved | PsA | |
| MRU-8112 | Merus | Preclinical | Huntington'sDMD | |
| Rilutinib | Repare | Phase 3 | SMAHeart Failure | |
| Zenotinib | Chugai | Phase 2/3 | PNHMDS | |
| IPN-129 | Ipsen | Approved | AngelmanWM | |
| RDY-8278 | Dr Reddy's | Phase 2/3 | DLBCL | |
| Talainavolisib | Boehringer Ingelheim | Phase 2/3 | FTD | |
| UCL-IIT-448 | UCLA Health | Phase 1 | Hemophilia A | |
| GOS-9676 | Gossamer Bio | Phase 1/2 | LGS | |
| INH-2936 | Inhibrx (Sanofi) | Phase 2 | PompeHCC | |
| RAP-6712 | RAPT Therapeutics | NDA/BLA | FLAtopic Derm | |
| Adagralemzoparlimab | CytomX Therapeutics | Phase 2/3 | FL | |
| GLY-2161 | GlycoMimetics | Phase 1/2 | TTR AmyloidosisEoE | |
| Fixaratamab | MiNT Therapeutics | Phase 1/2 | Urothelial CaADPKD | |
| Pemiosocimab | Achilles Therapeutics | Phase 1 | CF | |
| Doxasotorasib | Eloxx Pharma | Phase 1/2 | SchizophreniaRett | |
| GW-7331 | GW Pharma (Jazz) | Phase 3 | SMA | |
| INT-5527 | Interline Ther | Phase 2 | Ewing SarcomaHS | |
| Mirinaritide | Orbital Ther | Phase 2/3 | ALL | |
| NCN-3378 | NuCana | NDA/BLA | RSVWM | |
| DIC-4437 | Dicerna (Novo) | Approved | RA | |
| Suratapinarof | Istari Onc | NDA/BLA | FLCLL | |
| 415-3545 | Kyowa Kirin | Phase 2/3 | FTDSMA | |
| AUR-9187 | Aurobindo | Phase 2 | HSNB | |
| Elracapivasertib | PharmaMar | Approved | Atopic DermHNSCC | |
| NYK-4396 | Vaccibody (Nykode) | Preclinical | Hemophilia ALGS | |
| PHO-7143 | Photocure | Phase 2/3 | RettMigraine | |
| ORY-4744 | Oryzon Genomics | Phase 2/3 | Celiac | |
| SYN-6765 | Syncona | Approved | CeliacPSP | |
| DIV-3233 | Divi's Laboratories | Phase 2/3 | Cervical CaMM | |
| Dararelsin | Eurofarma | Preclinical | DLBCL | |
| RUI-IIT-267 | Ruijin Hospital | Approved | Hemophilia A | |
| AII-IIT-890 | AIIMS New Delhi | Approved | Prostate Ca | |
| HOS-IIT-275 | Hospital Israelita Einstein | Approved | Angelman | |
| RAB-IIT-533 | Rabin Medical Center | Preclinical | UC | |
| Teratinib | Dongbao Enterprise | NDA/BLA | LN | |
| Fixazasiran | Dermavant Sciences | Phase 2/3 | RAFTD | |
| DEC-1380 | Dechra Pharma (EQT) | Preclinical | CRCMDD | |
| Fixatinib | IDEXX Laboratories | Phase 2/3 | IPFGIST |